Allergan Reports Exceptional Fourth Quarter 2015 Continuing Operations Performance with 74% Increase in Net Revenue to $4.2 Billion and 33% Growth in Non-GAAP Diluted EPS to $3.41

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Allergan Reports Exceptional Fourth Quarter 2015 Continuing Operations Performance with 74% Increase in Net Revenue to $4.2 Billion and 33% Growth in Non-GAAP Diluted EPS to $3.41

Allergan's (AGN) Quarter Not Strong Enough to Support Price Target - PiperJaffray

February 23, 2016 8:23 AM EST

Allergan (NYSE: AGN) posted a solid 4Q leading Piper Jaffray analyst, David Amsellem, to reiterate his Overweight rating but trim his price target as estimates roll forward.

AGN reported non-GAAP diluted EPS of $3.41 on revenues of $4.2B, versus the Street estimates of $3.36 and $4.2B. Performance across several key product franchises remained strong, with total brand revenue in 4Q15 growing by 11% over 4Q14 (excluding foreign exchange headwinds and the erosion of the immediate-release form of Namenda due to generics).

The company has strong visibility on continued brisk volume growth for key... More

Mizuho Securities Reiterates Buy on Allergan (AGN) Following a 4Q Earnings Beat

February 23, 2016 7:04 AM EST

Mizuho Securities maintained a Buy rating on Allergen (NYSE: AGN), and cut the price target to $330.00 (from $354.00), following the company's 4Q earnings report. AGN delivered a solid 4Q bottom line beat with revenues of $4.2B and EPS of $3.41 versus consensus estimates $4.2B and... More

Allergan (AGN) Tops Q4 EPS by 5c

February 22, 2016 7:32 AM EST

Allergan (NYSE: AGN) reported Q4 EPS of $3.41, $0.05 better than the analyst estimate of $3.36. Revenue for the quarter came in at $4.2 billion versus the consensus estimate of $4.2 billion.

GUIDANCE:

Allergan sees FY2016 revenue of abot $17 billion, versus the consensus of $17.66... More